Published in Neurosci Lett on July 08, 2011
Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3? BMC Med (2013) 0.88
Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. Front Pharmacol (2014) 0.82
The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med (2014) 0.81
Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol (2013) 0.80
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Diagnosis of Alzheimer's disease. Arch Neurol (1985) 12.77
Statins and the risk of dementia. Lancet (2000) 5.65
Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A (1998) 4.49
Metabolism and function of coenzyme Q. Biochim Biophys Acta (2004) 3.83
Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology (2007) 3.67
Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 3.50
Biochemical functions of coenzyme Q10. J Am Coll Nutr (2001) 2.09
Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med (2004) 1.99
APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology (2005) 1.50
Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol (2004) 1.42
National trends in statin use by coronary heart disease risk category. PLoS Med (2005) 1.41
Effects of lovastatin on cognitive function and psychological well-being. Am J Med (2000) 1.32
Functions of coenzyme Q10 in inflammation and gene expression. Biofactors (2008) 1.32
Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim Biophys Acta (1992) 1.31
In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res (1994) 1.28
Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. Arch Biochem Biophys (2004) 1.21
Lovastatin decreases coenzyme Q levels in rats. Proc Natl Acad Sci U S A (1990) 1.20
Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci (2000) 1.18
Coenzyme Q, oxidative stress and aging. Mitochondrion (2007) 1.16
Visual-discrimination learning ability and beta-amyloid accumulation in the dog. Neurobiol Aging (1999) 1.13
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases. Arch Neurol (2010) 1.08
Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther (1993) 1.04
Beta-amyloid accumulation in aged canine brain: a model of early plaque formation in Alzheimer's disease. Neurobiol Aging (1994) 1.03
Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med (1989) 1.03
Effects of age, dietary, and behavioral enrichment on brain mitochondria in a canine model of human aging. Exp Neurol (2009) 0.97
Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol Dis (2006) 0.96
Coenzyme Q10 attenuates beta-amyloid pathology in the aged transgenic mice with Alzheimer presenilin 1 mutation. J Mol Neurosci (2008) 0.93
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res (2010) 0.87
Subchronic oral toxicity of ubiquinol in rats and dogs. Int J Toxicol (2008) 0.86
Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J Neurosci Res (1998) 0.86
Changes in cognition and amyloid-β processing with long term cholesterol reduction using atorvastatin in aged dogs. J Alzheimers Dis (2010) 0.86
Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro. Biochem Biophys Res Commun (2005) 0.84
Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: an in vivo volume MRI study. Biofactors (2008) 0.83
Can statins prevent or help treat Alzheimer's disease? J Alzheimers Dis (2010) 0.83
Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol (2002) 0.82
Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol (2002) 0.81
Bioavailability assessment of oral coenzyme Q10 formulations in dogs. Drug Dev Ind Pharm (2002) 0.80
Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol (1995) 0.80
Preservation of the blood brain barrier integrity may underlie neuroprotective effects of statins in Alzheimer's disease. J Alzheimers Dis (2006) 0.79
Effect on absorption and oxidative stress of different oral Coenzyme Q10 dosages and intake strategy in healthy men. Biofactors (2005) 0.79
Bioavailability of water-soluble CoQ10 in beagle dogs. J Pharm Biomed Anal (2008) 0.77
Brain aging in dogs: parallels with human brain aging and Alzheimer's disease. Vet Ther (2001) 0.76
Atorvastatin is not cataractogenic in beagle dogs. Curr Eye Res (1997) 0.76
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci (2007) 2.77
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med (2005) 2.51
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A (2002) 2.28
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med (2002) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology (2008) 1.94
Retracted Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun (2008) 1.91
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol (2002) 1.91
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging (2003) 1.78
Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv (2007) 1.74
APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology (2009) 1.74
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem (2002) 1.73
Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem (2003) 1.70
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem (2003) 1.67
Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci (2007) 1.65
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci (2005) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis (2005) 1.58
Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci (2009) 1.54
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Retracted Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem (2009) 1.53
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2005) 1.52
Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis (2002) 1.51
Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging (2005) 1.50
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A (2010) 1.45
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis (2010) 1.41
Nutrition, brain aging, and neurodegeneration. J Neurosci (2009) 1.40
Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis (2008) 1.38
Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem (2003) 1.38
Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal (2006) 1.37
Nitric oxide in cell survival: a janus molecule. Antioxid Redox Signal (2009) 1.37
Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem (2005) 1.37
Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J Nutr Biochem (2002) 1.35
Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging (2002) 1.34
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener (2010) 1.34
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun (2009) 1.32
Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem (2003) 1.32
Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis (2007) 1.32
The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis (2008) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma (2007) 1.30
Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav (2007) 1.28
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res (2008) 1.26
Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics (2005) 1.25
Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J Nutr Biochem (2008) 1.25
Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones (2007) 1.25
Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging (2005) 1.24
An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res (2007) 1.23
Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E epsilon2/epsilon2 genotype. Arch Neurol (2007) 1.22
Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res (2009) 1.22
Thyroid hormone, brain development, and the environment. Environ Health Perspect (2002) 1.22
Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis (2006) 1.22
Measurement of oxidized/reduced glutathione ratio. Methods Mol Biol (2010) 1.20
Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol (2006) 1.20
Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal (2006) 1.20
Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology (2008) 1.20
Free radicals and brain aging. Clin Geriatr Med (2004) 1.20
Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem (2007) 1.19
Locomotor activity rhythms in dogs vary with age and cognitive status. Behav Neurosci (2003) 1.19
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci (2008) 1.18
Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol (2010) 1.18
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging (2006) 1.17
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem (2009) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) (2009) 1.14
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) (2003) 1.11
Protein carbonylation. Antioxid Redox Signal (2010) 1.11
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11
Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. Drug News Perspect (2002) 1.10
Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: insight into chemobrain. Free Radic Res (2005) 1.10
Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Ital J Biochem (2003) 1.10
Lipopolysaccharide impairs amyloid β efflux from brain: altered vascular sequestration, cerebrospinal fluid reabsorption, peripheral clearance and transporter function at the blood-brain barrier. J Neuroinflammation (2012) 1.09
Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiol Aging (2005) 1.09
Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett (2003) 1.09
Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol (2009) 1.09